Stage IV is a dubious disease in the field of blood tumors, with complex clinical outcomes and often involving multi-system fatigue. Early identification and standardised diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical outcomes, imaging, laboratory testing and pathological activation.
The platform can assist in linking a team of authoritative experts at home and abroad to provide accurate diagnostic and therapeutic programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to the timely schedule according to the changes in the condition.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of Stage IV of Hodgkin's lymph nodes. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.